Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3020 Carrington Mill Blvd, Suite ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Key Takeaways TG Therapeutics reported Q4 EPS of 14 cents, missing estimates despite 78% revenue growth.Briumvi recorded $189.1M in Q4 revenues, with U.S. net sales rising 76% Y/Y and 20% sequentially.TGTX reaffirmed 2026 revenue guidance of $875M-$900M, with Briumvi sales expected to be $825-$850M.TG Therapeutics (TGTX) reported earnings of 14 cents per share for the fourth quarter of 2025, which substantially missed the Zacks Consensus Estimate of 35 cents. The company had reported earnings of 15 cents pe ...

The subcu portion of the anti-CD20 market is substantial and being able to compete in this space, we believe, could nearly double our total addressable market opportunity. Beyond MS, we are actively advancing plans to explore BRIUMVI in additional autoimmune indications, including having treated a series of Myasthenia Gravis patients in a Phase I study. And finally, Azer-cel, our allogeneic anti-CD19 CAR-T is being studied in patients with progressive MS. It's still early, but momentum is building. Our clin ...

TG Therapeutics (NasdaqCM:TGTX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAdam Waldman - Chief Commercialization OfficerCorinne Johnson - Vice President of Equity ResearchEmily Bodnar - Vice President of Equity ResearchJenna Bosco - VP of Corporate CommunicationsMichael Weiss - Chairman, President, and CEOSean Power - CFOConference Call ParticipantsBrian Cheng - Vice President and Equity Research AnalystMichael Schmidt - Managing Director and Equity Research AnalystPrakhar Agra ...

TG Therapeutics (NasdaqCM:TGTX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAdam Waldman - Chief Commercialization OfficerCorinne Johnson - Vice President of Equity ResearchEmily Bodnar - Vice President of Equity ResearchJenna Bosco - VP of Corporate CommunicationsMichael Weiss - Chairman and CEOSean Power - CFOConference Call ParticipantsBrian Cheng - Vice President and Equity Research AnalystMichael Schmidt - Managing Director and Equity Research AnalystPrakhar Agrawal - Senior ...

TG Therapeutics (NasdaqCM:TGTX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker7Greetings, welcome to the TG Therapeutics fourth quarter and year-end 2025 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I would now like to turn the conference o ...

Exhibit 99.1 TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately $875-900 million in total global revenue for 2026 Conference call to be held today, Thursday, February 26, 2026, at 8:30 AM ET New York, NY, (February 26, 2026) – TG Therapeutics, In ...

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately $875-900 million in total global revenue for 2026 Conference call to be held today, Thursday, February 26, 2026, at 8:30 AM ET NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and ...

Wall Street expects a year-over-year increase in earnings on higher revenues when TG Therapeutics (TGTX) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the ...